Serum anti-hepatitis B surface antigen in hemodialysis patients.

Rafieian-Kopaei, Mahmoud. and Nasri, Hamid. (2012) Serum anti-hepatitis B surface antigen in hemodialysis patients. Journal of nephropharmacology, 1 (1). pp. 3-5. ISSN 2345-4202

[img]
Preview
Text
14.pdf

Download (231kB) | Preview

Abstract

To evaluate the immune response to hepatitis B vaccination in stable hemodialysis (HD) patients, a retro-prospective investigation was conducted on 68 HD patients. Participants were vaccinated against hepatitis B virus with an intramuscular hepatitis B vaccination schedule, 40 micrograms at 0, 1, and 6 months. The serum antibody level against hepatitis B surface antigen (HBs) in HD patients was 35±55. In this study, no significant differences of Anti-HBs antibody between diabetic and non-diabetics or male and female subjects were observed. There were not any significant correlation between antibody against HBs-Ag and serum albumin. There was not significant correlation between anti-HBs antibody and age, proportion of HD, duration of HD or dialysis efficacy. In this study, there was not significant correlation between serum antibody level against hepatitis B surface antigen and some demographic indices of HD patients, however, these findings need to re-test in other centers with more participants.

Item Type: Article
Uncontrolled Keywords: Hepatitis B virus Hepatitis B vaccine Hemodialysis Anti-HBs antibody
Subjects: WJ Urogenital System
WK Endocrine System
QU Biochemistry
Divisions: Reserach Vice-Chancellar Department > Medical Plants Research Center
Depositing User: zahra bagheri .
Date Deposited: 15 Aug 2017 04:51
Last Modified: 30 May 2018 03:44
URI: http://eprints.skums.ac.ir/id/eprint/2963

Actions (login required)

View Item View Item